Publication date: Jun 27, 2026
With the ongoing global pandemic of coronavirus disease 2019 (COVID-19), the rational use of medications and clinical profiles in the afflicted children-a particularly susceptible group-warrant further investigation. This paper analyzed the rationality of medicinal treatments and clinical characteristics in children with COVID-19. We retrospectively reviewed the clinical data of pediatric inpatients with COVID-19 admitted to the Fifth Hospital of Xiamen from January 2025 to December 2025. Clinical classifications, symptoms, outcomes, complications and the use of therapeutic drugs were statistically analyzed. The rationality of medication was assessed by indication consistency and administration routes. The clinical cure and improvement rate reached 99. 22% in the 129 confirmed pediatric cases of COVID-19. They were categorized into a mild group (69 cases, 53. 49%), a moderate group (59 cases, 45. 74%), and a critical group (1 case, 0. 77%). Clinical manifestations mainly included fever, cough, and runny nose. A significant difference was evident between the mild group and the moderate group in age, weight, outcomes, and clinical symptoms (e. g., coughing, runny nose, and nasal congestion) (P
Open Access PDF
| Concepts | Keywords |
|---|---|
| Coronavirus | Children |
| December | Clinical features |
| Inpatients | COVID-19 |
| Mild | Drug treatment |
| Xiamen | SARS-CoV-2 |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | SARS-CoV-2 infection |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | included |
| disease | MESH | fever |
| disease | MESH | cough |
| disease | MESH | runny nose |
| pathway | REACTOME | Reproduction |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | pleural effusion |
| disease | MESH | respiratory failure |
| disease | MESH | shock |